On Oct 31, major Wall Street analysts update their ratings for $AtriCure (ATRC.US)$, with price targets ranging from $36 to $60.
J.P. Morgan analyst Robbie Marcus maintains with a buy rating, and adjusts the target price from $30 to $40.
UBS analyst Danielle Antalffy maintains with a buy rating, and adjusts the target price from $35 to $40.
Oppenheimer analyst Suraj Kalia maintains with a buy rating, and adjusts the target price from $32 to $36.
Needham analyst Michael Matson maintains with a buy rating, and adjusts the target price from $34 to $40.
Stifel analyst Rick Wise maintains with a buy rating, and adjusts the target price from $26 to $36.
Furthermore, according to the comprehensive report, the opinions of $AtriCure (ATRC.US)$'s main analysts recently are as follows:
AtriCure's recent quarter was described as 'exciting,' surpassing sales expectations by 3.4%, indicating a robust performance. Even considering some impact from PFA, the MIS Ablation business's underperformance is seen as not detrimental to the company's sustained mid-teens growth outlook. AtriCure continues to focus on enhancing profitability and anticipates achieving positive cash flow in FY25.
AtriCure's third-quarter revenues reached $116M, marginally surpassing the anticipated $113M and consensus estimate of $112M. Analysts maintain a tactically constructive stance on AtriCure, noting a favorable risk/reward profile with the company trading at approximately 2.7 times FY25 sales compared to its small-cap MedTech peers, which average around 3.7 times.
Here are the latest investment ratings and price targets for $AtriCure (ATRC.US)$ from 6 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間10月31日，多家華爾街大行更新了$AtriCure (ATRC.US)$的評級，目標價介於36美元至60美元。
摩根大通分析師Robbie Marcus維持買入評級，並將目標價從30美元上調至40美元。
瑞士銀行分析師Danielle Antalffy維持買入評級，並將目標價從35美元上調至40美元。
奧本海默控股分析師Suraj Kalia維持買入評級，並將目標價從32美元上調至36美元。
Needham分析師Michael Matson維持買入評級，並將目標價從34美元上調至40美元。
斯迪富分析師Rick Wise維持買入評級，並將目標價從26美元上調至36美元。
此外，綜合報道，$AtriCure (ATRC.US)$近期主要分析師觀點如下：
atricure最近的一個季度被描述爲「令人興奮」，銷售預期超出3.4％，表明表現強勁。即使考慮到PFA的一些影響，MIS消融業務的表現不佳也被視爲對公司持續保持中等十幾歲增長前景不會有害。atricure繼續專注於增強盈利能力，並預計在FY25實現正現金流。
atricure的第三季度營收達到11600萬美元，略高於預期的11300萬美元和共識預估的11200萬美元。分析師對atricure保持戰略性建設性態度，指出公司以大約2.7倍FY25銷售額的交易價格進行交易，較其小市值MedTech同行平均約3.7倍，具有有利的風險/回報配置。
以下爲今日6位分析師對$AtriCure (ATRC.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
